BMP2/7 heterodimer is a stronger inducer of bone regeneration in peri-implant bone defects model than BMP2 or BMP7 homodimer

Dental Materials Journal

Volumn 31, Issue 2, 2012, Pages 239-248

  Sun, Ping ^a   Wang, Jingxiao ^b   Zheng, Yuanna ^c   Fan, Yi ^a   Gu, Zhiyuan ^a,c  

^a ZHEJIANG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

BMP2 7 heterodimer; Bone regeneration; Collagen I; Implant; Osteocalcin

Indexed keywords

ALKALINE PHOSPHATASE; BONE AREA; BONE DEFECT; BONE FORMATION; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; COLLAGEN I; COLLAGEN SPONGE; CONTROL GROUPS; HETERODIMERS; HOMODIMERS; IMMUNOHISTOCHEMICAL STAINING; LOW DOSE; MINIPIGS; OSTEOBLASTOGENESIS; OSTEOCALCIN; PERI-IMPLANT BONES; SIDE EFFECT; TYPE I COLLAGEN;

BIOMOLECULES; COLLAGEN; DEFECTS; IMPLANTS (SURGICAL); PHOSPHATASES;

BONE;

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN; COLLAGEN TYPE 1; DRUG CARRIER; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; RECOMBINANT PROTEIN;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BIOSYNTHESIS; BONE REGENERATION; CHEMISTRY; COMPARATIVE STUDY; DIMERIZATION; DRUG EFFECT; FEMALE; MALE; METABOLISM; MINIPIG; OSTEOBLAST; PERIIMPLANTITIS; PROTEIN MULTIMERIZATION; RANDOMIZATION; SKULL; SWINE; TISSUE ENGINEERING; TOOTH IMPLANTATION;

ALKALINE PHOSPHATASE; ALVEOLAR BONE LOSS; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE REGENERATION; COLLAGEN; COLLAGEN TYPE I; DENTAL IMPLANTS; DIMERIZATION; DRUG CARRIERS; FEMALE; MALE; OSTEOBLASTS; OSTEOCALCIN; PERI-IMPLANTITIS; PROTEIN MULTIMERIZATION; RANDOM ALLOCATION; RECOMBINANT PROTEINS; SKULL; SWINE; SWINE, MINIATURE; TISSUE ENGINEERING;

EID: 84864192396     PISSN: 02874547     EISSN: 18811361     Source Type: Journal    
DOI: 10.4012/dmj.2011-191     Document Type: Article

References (40)

1. Barboza EP, de Souza RO, Caúla AL, Neto LG, Caúla Fde O, Duarte ME. Bone regeneration of localized chronic alveolar defects utilizing cell binding peptide associated with anorganic bovine-derived bone mineral: a clinical and histological study. J Periodontol 2002; 73: 1153-1159.
2. Carson JS, Bostrom MP. Synthetic bone scaffolds and fracture repair. Injury 2007; 38 Suppl 1: S33-S37.
3. Sugawara A, Fujikawa K, Takagi S, Chow LC. Histological analysis of calcium phosphate bone grafts for surgically created periodontal bone defects in dogs. Dent Mater J 2008; 27: 787-794.
4. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med 2008; 2: 1-13.
5. Yamaji K, Kawanami M, Matsumoto A, Odajima T, Nishitani Y, Iwasaka K, Yoshimitsu K, Yoshiyama M. Effects of Dose of Recombinant Human BMP-2 on Bone Formation at Palatal Sites in Young and Old Rats. Dent Mater J 2007; 26: 481-486.
6. Winn, SR, Hu Y, Sfeir C, Hollinger JO. Gene therapy approaches for modulating bone regeneration. Adv Drug Deliv Rev 2000; 42: 121-138.
7. Lutz R, Park J, Felszeghy E, Wiltfang J, Nkenke E, Schlegel KA. Bone regeneration after topical BMP-2-gene delivery in circumferential peri-implant bone defects. Clin Oral Implants Res 2008; 19: 590-599.
8. Zhao M, Zhao Z, Koh JT, Jin T, Franceschi RT. Combinatorial gene therapy for bone regeneration: Cooperative interactions between adenovirus vectors expressing bone morphogenetic proteins 2, 4, and 7. J Cell Biochem 2005; 95: 1-16.
9. Zheng Y, Wu G, Zhao J, Wang L, Sun P, Gu Z. rhBMP2/7 Heterodimer: An Osteoblastogenesis Inducer of Not Higher Potency but Lower Effective Concentration Compared with rhBMP2 and rhBMP7 Homodimers. Tissue Eng Part A 2010; 16: 879-887.
10. Wang J, Zheng Y, Zhao J, Liu T, Gao L, Gu Z, Wu G. Low-dose rhBMP2/7 heterodimer to reconstruct peri-implant bone defects: a micro-CT evaluation. J Clin Peridontol 2012; 39: 98-105.
11. Park J, Lutz R, Felszeghy E, Wiltfang J, Nkenke E, Neukam FW, Schlegel KA. The effect on bone regeneration of a liposomal vector to deliver BMP-2 gene to bone grafts in peri-implant bone defects. Biomaterials 2007; 28: 2772-2782.
12. Schlegel KA, Lang FJ, Donath K, Kulow JT, Wiltfang J. The monocortical critical size bone defect as an alternative experimental model in testing bone substitute materials. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 7-13.
13. Ohya M, Yamada Y, Ozawa R, Ito K, Takahashi M, Ueda M. Sinus floor elevation applied tissue-engineered bone. Comparative study between mesenchymal stem cells/ plateletrich plasma (PRP) and autogenous bone with PRP complexes in rabbits. Clin Oral Implants Res 2005; 16: 622-629.
14. Sun XJ, Zhang ZY, Wang SY, Gittens SA, Jiang XQ, Chou LL. Maxillary sinus floor elevation using tissue-engineered bone complex with OsteoBonet and bMSCs in rabbits. Clin Oral Implants Res 2008; 19: 804-813.
15. Hogan, BL. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev 1996; 10: 1580-1594.
16. Cochran DL, Jones AA, Lilly LC, Fiorellini JP, Howell H. Evaluation of recombinant human bone morphogenetic protein-2 in oral applications including the use of endosseous implants: 3-year results of a pilot study in humans. J Periodontol 2000; 71: 1241-1257.
17. Kirker-Head CA. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev 2000; 43: 65-92.
18. Franceschi RT. Biological approaches to bone regeneration by gene therapy. J Dent Res 2005; 84: 1093-1103.
19. Marukawa K, Ueki K, Alam S, Shimada M, Nakagawa K, Yamamoto E, Expression of bone morphogenetic protein-2 and proliferating cell nuclear antigen during distraction osteogenesis in the mandible in rabbits. Br J Oral Maxillofac Surg 2006; 44: 141-145.
20. Alam S, Ueki K, Marukawa K, Ohara T, Hase T, Takazakura D, Nakagawa K. Expression of bone morphogenetic protein 2 and fibroblast growth factor 2 during bone regeneration using different implant materials as an onlay bone graft in rabbit mandibles. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 16-26.
21. Giannobile WV, Ryan S, Shih MS, Su DL, Kaplan PL, Chan TC. Recombinant human osteogenic protein-1 (OP-1) stimulates periodontal wound healing in class III furcation defects. J Periodontol 1998; 69: 129-137.
22. Rutherford RB, Sampath TK, Rueger DC, Taylor TD. Use of bovine osteogenic protein to promote rapid osseointegration of endosseous dental implants. Int J Oral Maxillofac Implants 1992; 7: 297-301.
23. Van den Bergh JP, ten Bruggenkate CM, Groeneveld HH, Burger EH, Tuinzing DB. Recombinant human bone morphogenetic protein-7 in maxillary sinus floor elevation surgery in 3 patients compared to autogenous bone grafts: a clinical pilot study. J Clin Periodontol 2000; 27: 627-636.
24. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 2002; 27:2662-2673.
25. Toth JM, Boden SD, Burkus JK, Badura JM, Peckham SM, McKay WF. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine 2009; 34: 539-550.
26. Wiltfang J, Kloss FR, Kessler P, Nkenke E, Schultze-Mosgau S, Zimmermann R, Schlegel KA. Effects of platelet-rich plasma on bone healing in combination with autogenous bone and bone substitutes in critical-size defects -An animal experiment. Clin Oral Implants Res 2004; 15: 187-193.
27. Hollinger JO, Kleinschmidt JC. The critical size defect as an experimental model to test bone repair materials. J Craniofac Surg 1990; 2: 237-243.
28. Schmitz JP, Hollinger JO. The critical size defect as an experimental model for craniomandibular nonjunction. Clin Orthoped Relat Res 1986; 205: 299-308.
29. Bosch C, Melsen B, Vargervik K. Importance of the criticalsize bone defect in testing bone-regenerating materials. J Craniofac Surg 1998; 9: 310-316.
30. Cowan CM, Aghaloo T, Chou YF, Walder B, Zhang X, Soo C, Ting K, Wu B. MicroCT evaluation of three-dimensional mineralization in response to BMP-2 doses in vitro and in critical sized rat calvarial defects. Tissue Eng 2007; 13: 501-512.
31. Koh JT, Zhao Z, Wang Z, Lewis IS, Krebsbach PH, Franceschi RT. Combinatorial gene therapy with BMP2/7 enhances cranial bone regeneration. J Dent Res 2008; 87: 845-849.
32. Zhu W, Rawlins BA, Boachie-Adjei O, Myers ER, Arimizu J, Choi E, Lieberman JR, Crystal RG, Hidaka C. Combined bone morphogenetic protein-2 and-7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res 2004; 19: 2021-2032.
33. Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008; 19: 444-451.
34. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol 2008; 61: 577-587.
35. Hughes FJ, Turner W, Belibasakis G, Martuscelli G. Effects of growth factors and cytokines on osteoblast differentiation. Periodontol 2000 2006; 41: 48-72.
36. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 2002; 8: 147-159.
37. Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci 2007; 1116: 281-290.
38. Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000; 11 (Suppl 6): S18-S29.
39. Thorwarth M, Rupprecht S, Falk S, Felszeghy E, Wiltfang J, Schlegel KA. Expression of bone matrix proteins during de novo bone formation using a bovine collagen and platelet-rich plasma (PRP) -an immunohistochemical analysis. Biomaterials 2005; 26: 2575-2584.
40. Thorwarth M, Schlegel KA, Wehrhan F, Srour S, Schultze-Mosgau S. Acceleration of de novo bone formation following application of autogenous bone to particulated anorganic bovine material in vivo. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 309-316.